Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alluna is a non-prescription herbal sleep aid containing a fixed combination of valerian root extract (*Valeriana officinalis*) and hop cone extract (*Humulus lupulus*). Originally introduced by GSK, it is indicated for the treatment of restlessness, nervous sleep disorders, and insomnia in adults and adolescents aged 12 and older. Unlike many synthetic sedatives, Alluna is marketed as non-habit forming and supports the body's natural sleep architecture without suppressing REM or delta-stage sleep. The therapeutic effect is cumulative, typically requiring at least two weeks of consistent use to stabilize sleep patterns, with optimal results observed after one month of continuous administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alluna.